How to Help Your Patients Find RIMSO-50 in Stock: A Provider's Guide

Patients with interstitial cystitis (IC/BPS) rely on RIMSO-50 (dimethyl sulfoxide) to manage a painful, chronic condition. When supply disruptions occur, providers bear a dual burden: sourcing the medication for their clinic while simultaneously supporting patients who are frustrated and suffering. This guide provides a structured, practical approach to helping your patients navigate RIMSO-50 availability challenges in 2026.

Step 1: Know Your Supply Chain and Keep It Redundant

The most effective thing a urology practice can do is establish relationships with multiple specialty distributors before a supply issue arises. Relying on a single supplier creates a single point of failure. Identify at least two or three distributors — including at least one hospital-affiliated pharmaceutical wholesaler — and maintain open lines of communication with each.

Key distributors to consider:

McKesson Specialty Health

AmerisourceBergen Specialty Group

Cardinal Health Specialty Solutions

Local hospital pharmacy partnerships (academic medical centers often have broader supply access)

Step 2: Know the Generic — and Keep It as a Backup

Generic dimethyl sulfoxide 50% intravesical solution (Sandoz) is FDA-approved and bioequivalent to brand RIMSO-50. Stocking or being able to quickly order the generic creates a built-in fallback. Because it flows through slightly different distribution channels than the brand, it may be available when RIMSO-50 is temporarily backordered. Train your team to verify generic availability proactively rather than waiting for a brand stockout.

Step 3: Build a Proactive Ordering Calendar

Since IC bladder instillations follow a biweekly schedule, your practice has a reasonably predictable demand curve for RIMSO-50. Build an ordering calendar that places orders 2–3 weeks ahead of the next treatment cycle. This lead time is often enough to course-correct if a shipment is delayed or backordered. A small standing buffer stock — even just 1–2 extra units beyond scheduled appointments — can prevent patient disruptions.

Step 4: Identify Local Specialty and Hospital Pharmacies for Patient Referrals

In cases where your practice cannot obtain RIMSO-50 in time but a patient has an urgent need, it helps to have a short list of local specialty and hospital pharmacies that carry it. These pharmacies can potentially supply the drug directly for a clinical appointment. Build this list before it is needed — during a supply crisis is not the time to start making calls.

Specialty pharmacy networks that may carry RIMSO-50 include:

CVS Specialty

Walgreens Specialty Pharmacy

Optum Specialty Pharmacy

Shields Health Solutions (hospital-integrated specialty pharmacy)

Step 5: Provide Patients With a Pharmacy Search Resource

One of the most effective things you can do for patients is refer them to a resource that searches pharmacies on their behalf. medfinder is a service designed exactly for this purpose: patients provide their medication name, dosage, and location, and medfinder calls pharmacies to check which ones can fill the prescription, then texts the patient the results.

For IC patients who are already managing significant pain and disability, removing the burden of pharmacy phone calls can be a meaningful relief. Consider adding medfinder to your practice's patient resource handouts.

Step 6: Have a Ready Bridge Therapy Protocol

Every IC practice should have a written bridge therapy protocol for RIMSO-50 supply disruptions. This protocol should include decision criteria (who gets which bridge therapy), prescribing templates, and patient education materials. Suggested tiered approach:

Tier 1 (short-term, ≤4 weeks): Intravesical lidocaine cocktail (lidocaine + bicarbonate ± heparin) administered in-office or prescribed for home use. NSAIDs for pain management.

Tier 2 (extended gap, >4 weeks): Start or continue intravesical heparin instillations. Initiate or optimize oral therapy (amitriptyline, antihistamines). For Hunner-type IC, consider hydrodistension if symptom recurrence is severe.

Tier 3 (indefinite disruption): Initiate Elmiron as long-term background therapy. Consider neuromodulation (sacral nerve stimulation) referral for appropriate candidates. Document escalation rationale thoroughly.

Step 7: Communicate Proactively — Do Not Wait for Patients to Call

When RIMSO-50 supply is disrupted, notify affected patients before their scheduled appointment — ideally within 24–48 hours of identifying the issue. Patients with IC often have planned their day around a treatment that provides significant symptom relief. An unexpected cancellation is not merely an inconvenience; it can mean increased pain, missed work, and eroded trust in their care team.

A proactive outreach message should include: (1) the nature of the supply issue, (2) an estimated resolution timeline if known, (3) the bridge therapy being offered, and (4) whom to call with questions. This level of communication demonstrates care and builds long-term patient trust.

For more on the clinical context of RIMSO-50 supply disruptions, see: RIMSO-50 Shortage: What Providers Need to Know in 2026.